Dencatistat (STP938)
T-Cell Lymphomas (e.g., Peripheral T-Cell Lymphoma)
Key Facts
About Step Pharma
Step Pharma is a clinical-stage oncology company pioneering the development of CTPS1 inhibitors, a novel therapeutic approach targeting a critical enzyme in nucleotide synthesis. The company's lead candidate, dencatistat (STP938), is a first-in-class, oral, selective inhibitor entering clinical trials with an initial focus on lymphomas and solid tumors like ovarian cancer. Step Pharma's strategy leverages a synthetic lethal approach, particularly targeting cancers with loss of the CTPS2 isoform, aiming for a selective and potentially safer cancer therapy. The company is privately held and operates from its base in the Lyon biotech hub.
View full company profileAbout Step Pharma
Step Pharma is a clinical-stage oncology company pioneering the development of CTPS1 inhibitors, a novel therapeutic approach targeting a critical enzyme in nucleotide synthesis. The company's lead candidate, dencatistat (STP938), is a first-in-class, oral, selective inhibitor entering clinical trials with an initial focus on lymphomas and solid tumors like ovarian cancer. Step Pharma's strategy leverages a synthetic lethal approach, particularly targeting cancers with loss of the CTPS2 isoform, aiming for a selective and potentially safer cancer therapy. The company is privately held and operates from its base in the Lyon biotech hub.
View full company profileAbout Step Pharma
Step Pharma is a clinical-stage oncology company pioneering the development of CTPS1 inhibitors, a novel therapeutic approach targeting a critical enzyme in nucleotide synthesis. The company's lead candidate, dencatistat (STP938), is a first-in-class, oral, selective inhibitor entering clinical trials with an initial focus on lymphomas and solid tumors like ovarian cancer. Step Pharma's strategy leverages a synthetic lethal approach, particularly targeting cancers with loss of the CTPS2 isoform, aiming for a selective and potentially safer cancer therapy. The company is privately held and operates from its base in the Lyon biotech hub.
View full company profileAbout Step Pharma
Step Pharma is a clinical-stage oncology company pioneering the development of CTPS1 inhibitors, a novel therapeutic approach targeting a critical enzyme in nucleotide synthesis. The company's lead candidate, dencatistat (STP938), is a first-in-class, oral, selective inhibitor entering clinical trials with an initial focus on lymphomas and solid tumors like ovarian cancer. Step Pharma's strategy leverages a synthetic lethal approach, particularly targeting cancers with loss of the CTPS2 isoform, aiming for a selective and potentially safer cancer therapy. The company is privately held and operates from its base in the Lyon biotech hub.
View full company profile